Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti‐seizure medication
Open Access
- 12 October 2023
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (2) , 301-310
Abstract
Treatment‐resistant epilepsy is among the most serious complications of cardiofaciocutaneous syndrome (CFCS), a rare disorder caused by germline variants in the RAS‐MAPK signaling pathway. This study analyzed the clinical characteristics of epilepsy and response to anti‐seizure medications (ASMs) in a multinational CFCS cohort. A caregiver survey provided data regarding seizure history, use of ASMs and other treatment approaches, adverse effects, caregiver perception of treatment response, and neurological disease burden impact among individuals with CFCS. Results from 138 survey responses were quantitatively analyzed in conjunction with molecular genetic results and neurological records. The disease burden impact of CFCS was higher among individuals with epilepsy ( n = 74/138), especially those with more severe seizure presentation. Oxcarbazepine, a sodium‐channel blocker, had the best seizure control profile with relatively infrequent adverse effects. The most commonly prescribed ASM, levetiracetam, demonstrated comparatively poor seizure control. ASM efficacy was generally similar for individuals with BRAF and MAP2K1 gene variants. The high proportion of patients with CFCS who experienced poor seizure control despite use of multiple ASMs highlights a substantial unmet treatment need. Prospective study of ASM efficacy and clinical trials of therapies to attenuate RAS‐MAPK signaling may improve avenues for clinical management.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR002494)
- National Center for Advancing Translational Sciences (KL2TR002492)
- National Institute of Neurological Disorders and Stroke (K23NS123258)
This publication has 31 references indexed in Scilit:
- Cardio-Facio-Cutaneous Syndrome: Clinical Features, Diagnosis, and Management GuidelinesPediatrics, 2014
- The consequences of refractory epilepsy and its treatmentEpilepsy & Behavior, 2014
- A survey of seizures and current treatments in 15q duplication syndromeEpilepsia, 2014
- Prevalence and clinical features of Costello syndrome and cardio‐facio‐cutaneous syndrome in Japan: Findings from a nationwide epidemiological surveyAmerican Journal of Medical Genetics Part A, 2012
- Cardio-facio-cutaneous syndrome with infantile spasms and delayed myelinationBrain and Development, 2011
- Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascadeAmerican Journal of Medical Genetics Part A, 2009
- The Early Childhood Epilepsy Severity Scale (E-Chess)Epilepsy Research, 2008
- Neurological complications of cardio‐facio‐cutaneous syndromeDevelopmental Medicine & Child Neurology, 2007
- Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous SyndromeScience, 2006
- Assessing the impact of pediatric epilepsy and concomitant behavioral, cognitive, and physical/neurologic disability: Impact of Childhood Neurologic Disability ScaleDevelopmental Medicine & Child Neurology, 2003